← Shuttle Pharmaceuticals (SHPH)

Shuttle Pharmaceuticals SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

  • 8-KNov. 19, 2026, 5 p.m. ETView on SEC.govOur explainer

    Entry into a material definitive agreement · Unregistered sales of equity securities · Other events · Financial statements and exhibits

    AI summary, unreviewedShuttle Pharmaceuticals Holdings issues 6,693,740 milestone pre-funded warrants at $0.001 exercise price, adding dilution against ~4.8M shares outstanding

  • 8-KNov. 6, 2026, 5:25 p.m. ETView on SEC.gov

    Change in certifying accountant · Financial statements and exhibits

    AI summary, unreviewedShuttle Pharmaceuticals Holdings Replaces Forvis Mazars with Bush & Associates CPA as Auditor Effective November 2, 2026

  • 8-KOct. 22, 2026, 4:30 p.m. ETView on SEC.gov

    Change in certifying accountant · Financial statements and exhibits

    AI summary, unreviewedShuttle Pharmaceuticals Holdings dismisses auditor Forvis Mazars amid material weaknesses and no replacement engaged

  • 10-QSept. 24, 2026, 12:01 p.m. ETView on SEC.gov
  • 8-K/ASept. 24, 2026, 12 p.m. ETView on SEC.gov

    Financial statements and exhibits

  • 8-KSept. 15, 2026, 6:15 p.m. ETView on SEC.gov

    Unregistered sales of equity securities · Financial statements and exhibits

  • 8-KSept. 11, 2026, 7:30 a.m. ETView on SEC.gov

    Submission of matters to a vote of security holders · Financial statements and exhibits

  • 8-KSept. 2, 2026, 3 p.m. ETView on SEC.gov

    Other events · Financial statements and exhibits

  • 8-KSept. 1, 2026, 4:05 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Financial statements and exhibits

  • 8-KAug. 28, 2026, 4:45 p.m. ETView on SEC.gov

    Delisting notice / failure to meet listing standard · Regulation FD disclosure · Financial statements and exhibits

  • 8-K/AAug. 17, 2026, 5:03 p.m. ETView on SEC.gov

    Completion of acquisition or disposition of assets · Financial statements and exhibits